CN114380864A - 一种双氢青蒿素衍生物、制备方法、药物组合物和其在制备抗肿瘤药物中的应用 - Google Patents
一种双氢青蒿素衍生物、制备方法、药物组合物和其在制备抗肿瘤药物中的应用 Download PDFInfo
- Publication number
- CN114380864A CN114380864A CN202111626019.3A CN202111626019A CN114380864A CN 114380864 A CN114380864 A CN 114380864A CN 202111626019 A CN202111626019 A CN 202111626019A CN 114380864 A CN114380864 A CN 114380864A
- Authority
- CN
- China
- Prior art keywords
- dihydroartemisinin
- cancer
- reaction
- derivative
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- 150000000138 dihydroartemisinin derivatives Chemical class 0.000 title claims abstract description 29
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 7
- 239000002246 antineoplastic agent Substances 0.000 title abstract description 9
- 229940041181 antineoplastic drug Drugs 0.000 title abstract description 9
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims abstract description 34
- BJDCWCLMFKKGEE-ISOSDAIHSA-N artenimol Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-ISOSDAIHSA-N 0.000 claims abstract description 12
- 229960002521 artenimol Drugs 0.000 claims abstract description 12
- 229930016266 dihydroartemisinin Natural products 0.000 claims abstract description 12
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 6
- 150000002367 halogens Chemical class 0.000 claims abstract description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 66
- 150000001875 compounds Chemical class 0.000 claims description 47
- 238000006243 chemical reaction Methods 0.000 claims description 44
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 36
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical group FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 claims description 21
- 206010005003 Bladder cancer Diseases 0.000 claims description 15
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 15
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 9
- 230000000259 anti-tumor effect Effects 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 239000013078 crystal Substances 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 3
- 229940002612 prodrug Drugs 0.000 claims description 3
- 239000000651 prodrug Substances 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 230000003287 optical effect Effects 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 239000011541 reaction mixture Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 40
- 230000000694 effects Effects 0.000 abstract description 8
- 238000013508 migration Methods 0.000 abstract description 5
- 230000005012 migration Effects 0.000 abstract description 5
- 210000004881 tumor cell Anatomy 0.000 abstract description 5
- 230000035755 proliferation Effects 0.000 abstract description 2
- 238000001212 derivatisation Methods 0.000 abstract 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 58
- 239000011734 sodium Substances 0.000 description 38
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 29
- 238000005160 1H NMR spectroscopy Methods 0.000 description 29
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 29
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 22
- 238000012544 monitoring process Methods 0.000 description 21
- 238000004440 column chromatography Methods 0.000 description 20
- 238000012795 verification Methods 0.000 description 20
- 238000001035 drying Methods 0.000 description 18
- 239000000243 solution Substances 0.000 description 13
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 12
- 229910000027 potassium carbonate Inorganic materials 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- 239000013067 intermediate product Substances 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 description 4
- 229930101531 artemisinin Natural products 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- -1 artemisin ester Chemical class 0.000 description 3
- 229960004191 artemisinin Drugs 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 239000008055 phosphate buffer solution Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 230000000078 anti-malarial effect Effects 0.000 description 2
- 150000008378 aryl ethers Chemical class 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 230000003021 clonogenic effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000001700 mitochondrial membrane Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LGZMUUBPTDRQQM-UHFFFAOYSA-N 10-Bromo-1-decanol Chemical compound OCCCCCCCCCCBr LGZMUUBPTDRQQM-UHFFFAOYSA-N 0.000 description 1
- XFGANBYCJWQYBI-UHFFFAOYSA-N 11-bromoundecan-1-ol Chemical compound OCCCCCCCCCCCBr XFGANBYCJWQYBI-UHFFFAOYSA-N 0.000 description 1
- RQFUZUMFPRMVDX-UHFFFAOYSA-N 3-Bromo-1-propanol Chemical compound OCCCBr RQFUZUMFPRMVDX-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- SIJLYRDVTMMSIP-UHFFFAOYSA-N 4-Bromo-1-butanol Chemical compound OCCCCBr SIJLYRDVTMMSIP-UHFFFAOYSA-N 0.000 description 1
- WJVQJXVMLRGNGA-UHFFFAOYSA-N 5-bromopentan-1-ol Chemical compound OCCCCCBr WJVQJXVMLRGNGA-UHFFFAOYSA-N 0.000 description 1
- FCMCSZXRVWDVAW-UHFFFAOYSA-N 6-bromo-1-hexanol Chemical compound OCCCCCCBr FCMCSZXRVWDVAW-UHFFFAOYSA-N 0.000 description 1
- MMXRRNUXCHUHOE-UHFFFAOYSA-N 7-bromoheptan-1-ol Chemical compound OCCCCCCCBr MMXRRNUXCHUHOE-UHFFFAOYSA-N 0.000 description 1
- GMXIEASXPUEOTG-UHFFFAOYSA-N 8-bromooctan-1-ol Chemical compound OCCCCCCCCBr GMXIEASXPUEOTG-UHFFFAOYSA-N 0.000 description 1
- USJDOLXCPFASNV-UHFFFAOYSA-N 9-bromononan-1-ol Chemical compound OCCCCCCCCCBr USJDOLXCPFASNV-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- ASIDMJNTHJYVQJ-UHFFFAOYSA-N bromo-dodecanol Chemical compound OCCCCCCCCCCCCBr ASIDMJNTHJYVQJ-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000010370 cell cloning Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229910001448 ferrous ion Inorganic materials 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 125000002081 peroxide group Chemical group 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- USFPINLPPFWTJW-UHFFFAOYSA-N tetraphenylphosphonium Chemical compound C1=CC=CC=C1[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 USFPINLPPFWTJW-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种双氢青蒿素衍生物、制备方法、药物组合物和其在制备抗肿瘤药物中的应用，所述双氢青蒿素衍生物的结构为如下式Ⅰ所示：
其中，所述n为3‑12，R1为三苯基膦，R2为卤素；其可以显著抑制肿瘤细胞的增殖和迁移，IC50达到nM级别，大大低于衍生化前的双氢青蒿素；在OVCAR3、SKOV3、A549、T24和J82细胞系中，本发明双氢青蒿素衍生物活性较衍生化前的双氢青蒿素显著提高。
Description
技术领域
本发明涉及医药技术领域，具体地说，涉及一种双氢青蒿素衍生物、制备方法、药物组合物和其在制备抗肿瘤药物中的应用。
背景技术
癌症是继缺血性心脏病之后世界第二大死亡原因(897万人)，2060年后有可能成为世界第一大死亡原因(约1863万人)。据统计，2018年全球新增确诊病例1800万例，2020年新增病例还在持续上升。
双氢青蒿素是一种传统的一线抗疟疾的药物，近年来发现其除了具有抗疟疾的活性外还具有抗肿瘤活性。但是其发挥抗肿瘤作用的剂量远远高于其发挥抗疟疾的剂量，并且此类化合物的神经毒性问题一直是限制此类化合物应用的主要原因。开发有较高生物活性和较低副作用的双氢青蒿素类抗癌药物非常重要和迫切。
双氢青霉素衍生物的合成及抗癌活性研究，朴明男，延边大学硕士学位论文，2011年，公开了：在青蒿素的抗肿瘤作用机制研究中，认为最主要的机制为诱导细胞凋亡和亚铁离子作用过氧键基团，反应产生氧自由基损伤癌细胞膜性结构，但是确切的作用靶点和机制并不明确。
为了寻找比青蒿素抗肿瘤作用更强的药物，在保留过氧桥键的基础上，主要在双氢青蒿素10位碳上的-OH键引入一些亲水、亲脂基团进行结构修饰，合成了烷基醚、芳香醚、酯类、杂原子取代、二聚体化合物等青蒿素衍生物，并筛选出部分烷基醚、芳香醚类和部分双活性二聚体化合物比青蒿素具有更强的抗肿瘤活性。
线粒体是细胞内重要的亚细胞器，其与细胞的死亡密切相关。目前，靶向线粒体的药物研发已经成为该领域的研究热点。由于肿瘤细胞线粒体内膜电位比正常细胞更高，线粒体靶向基团TPP+可以依据线粒体膜电势的差异积聚在肿瘤细胞线粒体内，一般认为，靶向基团只会提高药物活性成分的靶向能力，对体外抗肿瘤细胞活性的提升并不会有明显影响。
Synthesis and biological activities of novel mitochondria-targetedartemisinin ester derivatives，Cangcang，Xu，Bioorg.Med.Chem.Lett.39(2021)127912，发明人将双氢青蒿素和
反应得到产物，制备路线如下所示。产物2a-2d对各肿瘤细胞的IC50值可以最低达到2.7μM，但是2d相比于DHA，其抗肿瘤活性的提升并不明显。
发明内容
本发明的目的是针对现有技术中的不足，提供一类双氢青蒿素衍生物、制备方法、药物组合物和其在制备抗肿瘤药物中的应用，双氢青蒿素衍生物的抗肿瘤活性较高，其IC50值达到nM级别，具有开发为良好抗肿瘤药物的应用前景。
本发明提供一种双氢青蒿素衍生物，所述双氢青蒿素衍生物的结构为如下式Ⅰ所示：
其中，所述n为3-12，R1为三苯基膦，R2为卤素，比如溴、氯、碘，优选为溴，其他卤素元素如氯、碘取代也具有类似的性能。
具体的，所述双氢青蒿素衍生物为以下化合物之一：
本发明优选的化合物为D7-T和D8-T，最优选的为化合物D8-T。
优选的，所述双氢青蒿素衍生物为式Ⅰ化合物的各光学异构体、各晶型、药学上可接受的无机盐、有机盐或前药。
本发明的盐可以由化合物中带正电荷的部分与具有相反电性的带负电荷形成；或者由化合物中带负电荷的部分与正电荷形成。
所述的“结构式Ⅰ的前药”通常指一种物质，当用适当的方法施用后，可在受试者体内进行代谢或化学反应而转变成结构式Ⅰ的至少一种化合物或其盐。
本发明的化合物可按照常规方法制备为药用盐的形式；包括其有机酸盐及无机酸盐：无机酸包括(但不限于)盐酸、硫酸、磷酸、二磷酸、氢溴酸、硝酸等，有机酸包括(但不限于)乙酸、马来酸、富马酸、酒石酸、琥珀酸、乳酸、对甲苯磺酸、水杨酸、草酸等。
本发明提供一种双氢青蒿素衍生物的制备方法，步骤为，将双氢青蒿素和
反应，n为3-12，R2为卤素，得到中间体，中间体的结构式如下：
中间体和三苯基膦反应，得到双氢青蒿素衍生物。
优选反应路线如下：
优选的，所述双氢青蒿素和
反应的溶剂为二氯甲烷，催化剂为三氟化硼***，优选在氮气保护下进行。
优选的，中间体和三苯基膦反应的溶剂为乙氰，反应体系中还加入有碳酸盐，如碳酸钾或碳酸钠，其作为碱催化剂。
本发明提供一种药物组合物，所述的药物组合物包括双氢青蒿素衍生物，还包括药学上可接受的赋形剂或载体。
本发明提供一种双氢青蒿素衍生物在制备抗肿瘤药物中的用途。所述肿瘤为肺癌、食道癌、胃癌、肝癌、黑色素瘤、胰腺癌、肾癌、白血病、***癌、膀胱癌、神经母细胞瘤、结肠癌、乳腺癌、子宫癌、卵巢癌或鼻咽癌。
本发明的有益效果是，本发明的实验结果显示双氢青蒿素衍生物能显著抑制肿瘤细胞的增殖和迁移，IC50大大低于衍生化前的双氢青蒿素，其中以化合物D7-T、D8-T的活性最好，在J82、OVCAR3和A549细胞中，本发明的双氢青蒿素衍生物活性是双氢青蒿素的2366、874和220倍，具有开发为良好抗肿瘤药物的应用前景。
附图说明
图1为D3-T～D12-T在5种癌细胞株中的半数抑制浓度(IC50)。
图2为D8-T和DHA对人膀胱癌细胞系T24和J82的克隆形成能力抑制效果染色图。
图3为D8-T和DHA对人膀胱癌细胞系T24和J82的克隆形成能力抑制效果柱状图。
图4为D8-T对人膀胱癌细胞系T24和J82迁移的抑制效果图。
图5为DHA对人膀胱癌细胞系T24和J82迁移的抑制效果图。
具体实施方式
以下具体的实例用以详细说明本发明，但本发明绝非仅限于这些例子(除另有注明外，所用原料均有市售)。
实施例1：中间体D3的制备
将DHA(1g，3.5mmol)溶于200mL二氯甲烷中配成溶液，在室温条件下加入3-溴-1-丙醇(0.325mL，3.6mmol)，再加入4滴三氟化硼***，N2保护，室温反应12h，TLC监测反应。反应结束，加入200mL饱和碳酸氢钠、二氯甲烷萃取三次，再加入无水碳酸钠干燥，过滤拌样，柱层析得中间产物D3，产率12.93％。
结构验证：
β-isomer；1H NMR(600MHz,Chloroform-d)δ5.42(s,1H),4.80(d,J＝3.5Hz,1H),4.00(ddd,J＝10.0,6.6,5.1Hz,1H),3.49(q,J＝6.4Hz,3H),2.64(qdd,J＝7.5,4.7,3.5Hz,1H),2.37(ddd,J＝14.7,13.5,4.0Hz,1H),2.15–1.99(m,3H),1.88(dddd,J＝13.7,6.8,4.0,3.1Hz,1H),1.80–1.69(m,2H),1.63(dq,J＝13.2,3.4Hz,1H),1.55–1.44(m,2H),1.44(s,3H),1.33(qp,J＝9.7,3.7,3.3Hz,1H),1.28–1.21(m,2H),0.95(d,J＝6.4Hz,3H),0.90(d,J＝7.4Hz,3H).13CNMR(150MHz,Chloroform-d)δ104.12,102.11,87.93,81.05,65.70,52.58,44.39,37.46,36.43,34.64,32.55,30.90,30.61,26.20,24.67,24.52,20.37,12.98.ESI-MS m/z:C18H29BrO5 427.2(M+Na)+:429.2(M+2+Na)+＝1:1。
α-isomer；1H NMR(600MHz,Chloroform-d)δ5.34(s,1H),4.44(d,J＝9.2Hz,1H),4.07(dt,J＝10.1,5.1Hz,1H),3.64–3.47(m,3H),2.46–2.32(m,2H),2.21(ddq,J＝16.7,8.5,5.6Hz,1H),2.09–1.96(m,2H),1.88(ddt,J＝13.6,6.8,3.5Hz,1H),1.76(dq,J＝13.6,3.7Hz,1H),1.72–1.66(m,1H),1.57–1.46(m,2H),1.43(s,3H),1.36–1.26(m,3H),1.04–0.98(m,1H),0.96(dd,J＝6.8,4.7Hz,3H),0.89(d,J＝7.1Hz,3H).13C NMR(150MHz,Chloroform-d)δ104.29,100.42,91.21,80.35,66.45,51.65,45.33,37.39,36.32,34.24,32.78,32.67,30.83,26.06,24.72,22.21,20.29,12.58.ESI-MS m/z:C18H29BrO5 427.2(M+Na)+:429.2(M+2+Na)+＝1:1。
实施例2：中间体D4的制备
将DHA(1g，3.5mmol)溶于200mL二氯甲烷中配成溶液，在室温条件下加入4-溴-1-丁醇(0.328mL，3.6mmol)，再加入4滴三氟化硼***，N2保护，室温反应12h，TLC监测反应。反应结束，加入200mL饱和碳酸氢钠、二氯甲烷萃取三次，再加入无水碳酸钠干燥，过滤拌样，柱层析得中间产物D4，产率10.09％。
结构验证：
β-isomer；1H NMR(600MHz,Chloroform-d)δ5.37(s,1H),4.77(d,J＝3.5Hz,1H),3.88(dt,J＝9.8,6.2Hz,1H),3.50–3.35(m,3H),2.69–2.57(m,1H),2.36(ddd,J＝14.7,13.5,4.0Hz,1H),2.03(ddd,J＝14.6,5.0,3.0Hz,1H),1.97–1.84(m,3H),1.79–1.68(m,4H),1.63(dq,J＝13.3,3.4Hz,1H),1.54–1.44(m,2H),1.43(s,3H),1.33(ttd,J＝12.4,6.3,4.0Hz,1H),1.28–1.15(m,2H),0.95(d,J＝6.4Hz,3H),0.90(d,J＝7.4Hz,3H).13C NMR(150MHz,Chloroform-d)δ104.10,102.01,87.92,81.10,67.44,52.58,44.42,37.49,36.44,34.64,33.63,30.90,29.82,28.34,26.21,24.68,24.50,20.37,13.04.ESI-MS m/z:C19H31BrO5 441.2(M+Na)+:443.2(M+2+Na)+＝1:1。
α-isomer；1H NMR(600MHz,Chloroform-d)δ5.44(s,1H),4.96(d,J＝5.2Hz,1H),3.91(dt,J＝9.8,6.3Hz,1H),3.51(dt,J＝9.9,6.4Hz,1H),3.45(t,J＝6.8Hz,2H),2.30(td,J＝14.0,3.9Hz,1H),2.02(ddd,J＝14.5,4.8,3.0Hz,1H),1.97(dq,J＝9.7,7.0Hz,2H),1.90(ddq,J＝13.5,6.6,3.5Hz,1H),1.76(p,J＝6.9Hz,2H),1.72–1.61(m,3H),1.55–1.47(m,2H),1.47–1.42(m,2H),1.42(s,3H),1.18(d,J＝7.2Hz,3H),0.99(td,J＝12.3,11.7,4.1Hz,1H),0.94(d,J＝5.9Hz,3H),0.93–0.86(m,1H).13C NMR(150MHz,Chloroform-d)δ103.01,102.78,89.17,81.67,67.77,51.86,46.55,39.89,37.32,36.53,34.42,33.71,31.64,29.74,28.34,25.98,24.69,20.07,19.51.ESI-MS m/z:C19H31BrO5 441.2(M+Na)+:443.2(M+2+Na)+＝1:1。
实施例3：中间体D5的制备
将DHA(1g，3.5mmol)溶于200mL二氯甲烷中配成溶液，在室温条件下加入5-溴-1-戊醇(0.438mL，3.6mmol)，再加入4滴三氟化硼***，N2保护，室温反应12h，TLC监测反应。反应结束，加入200mL饱和碳酸氢钠、二氯甲烷萃取三次，再加入无水碳酸钠干燥，过滤拌样，柱层析得中间产物D5，产率19.72％。
结构验证：
β-isomer；1H NMR(600MHz,Chloroform-d)δ5.39(s,1H),4.77(d,J＝3.4Hz,1H),3.85(dt,J＝9.8,6.3Hz,1H),3.47–3.32(m,3H),2.68–2.52(m,1H),2.42–2.30(m,1H),2.03(ddd,J＝14.6,5.0,3.0Hz,1H),1.91–1.84(m,3H),1.81(dd,J＝13.9,3.6Hz,1H),1.75(tt,J＝14.3,3.8Hz,1H),1.66–1.55(m,4H),1.54–1.45(m,4H),1.43(s,3H),1.42–1.28(m,3H),1.28–1.16(m,1H),0.95(d,J＝6.4Hz,3H),0.90(d,J＝7.8Hz 3H).13C NMR(150MHz,Chloroform-d)δ104.08,102.01,87.93,81.15,68.03,52.59,44.46,37.47,36.45,34.68,33.84,32.43,30.94,28.84,26.23,24.98,24.69,24.50,20.37,13.05.ESI-MS m/z:C20H33BrO5 455.2(M+Na)+:457.2(M+2+Na)+＝1:1。
α-isomer；1H NMR(600MHz,Chloroform-d)δ5.44(s,1H),4.95(d,J＝5.0Hz,1H),3.87(dt,J＝9.8,6.5Hz,1H),3.48(dt,J＝9.8,6.5Hz,1H),3.41(t,J＝6.8Hz,2H),2.30(ddd,J＝14.6,13.4,3.9Hz,1H),2.01(ddd,J＝14.6,4.8,3.1Hz,1H),1.89(ddt,J＝13.9,9.7,5.3Hz,3H),1.71(qd,J＝13.4,3.4Hz,2H),1.63(ddt,J＝12.0,8.2,4.8Hz,4H),1.57(dt,J＝13.3,3.5Hz,2H),1.54–1.49(m,3H),1.41(s,3H),1.18(d,J＝7.3Hz,3H),1.00–0.96(m,1H),0.94(d,J＝6.1Hz,3H),0.90–0.85(m,1H).13C NMR(150MHz,Chloroform-d)δ103.04,102.80,89.10,81.66,68.40,51.89,46.52,39.82,37.30,36.53,34.44,33.78,32.54,31.61,28.83,25.98,24.92,24.69,20.07,19.54.ESI-MS m/z:C20H33BrO5 455.2(M+Na)+:457.2(M+2+Na)+＝1:1。
实施例4：中间产物D6的制备
将DHA(1g，3.5mmol)溶于200mL二氯甲烷中配成溶液，在室温条件下加入6-溴-1-己醇(0.471mL，3.6mmol)，再加入4滴三氟化硼***，N2保护，室温反应12h，TLC监测反应。反应结束，加入200mL饱和碳酸氢钠、二氯甲烷萃取三次，再加入无水碳酸钠干燥，过滤拌样，柱层析得中间产物D6，产率13.10％。
结构验证：
β-isomer；1H NMR(600MHz,Chloroform-d)δ5.38(s,1H),4.77(d,J＝3.5Hz,1H),3.83(dt,J＝9.7,6.5Hz,1H),3.40(t,J＝6.8Hz,2H),3.36(dd,J＝9.7,6.4Hz,1H),2.61(qt,J＝7.4,4.1Hz,1H),2.40–2.32(m,1H),2.03(ddd,J＝14.6,5.0,3.0Hz,1H),1.90–1.83(m,3H),1.80(dd,J＝13.7,3.6Hz,1H),1.75(tq,J＝12.0,3.9Hz,1H),1.66–1.59(m,1H),1.58(d,J＝4.2Hz,2H),1.56–1.45(m,4H),1.44(s,3H),1.42–1.28(m,4H),1.24–1.16(m,1H),0.95(d,J＝6.3Hz,3H),0.90(d,J＝7.3Hz,3H).13C NMR(150MHz,Chloroform-d)δ104.07,101.99,87.92,81.15,68.24,52.61,44.48,37.51,36.46,34.68,33.80,32.73,30.95,29.49,27.89,26.24,25.46,24.70,24.49,20.39,13.05.ESI-MS m/z:C21H35BrO5469.3(M+Na)+:471.3(M+2+Na)+＝1:1。
α-isomer；1H NMR(600MHz,Chloroform-d)δ5.33(s,1H),4.41(d,J＝9.2Hz,1H),3.97(dt,J＝9.6,6.3Hz,1H),3.47–3.35(m,3H),2.49–2.28(m,2H),2.02(ddd,J＝14.6,5.0,3.0Hz,1H),1.87(h,J＝6.8Hz,3H),1.76(dq,J＝13.5,3.8Hz,1H),1.66(dddd,J＝33.0,15.3,7.8,4.7Hz,2H),1.57–1.45(m,4H),1.44(s,4H),1.42–1.27(m,5H),1.01(td,J＝12.7,12.2,3.2Hz,1H),0.95(d,J＝6.3Hz,3H),0.88(d,J＝7.1Hz,3H).13C NMR(150MHz,Chloroform-d)δ104.25,100.12,91.21,80.35,68.86,51.69,45.35,37.39,36.35,34.27,33.94,32.75,32.64,29.37,27.93,26.08,25.21,24.72,22.22,20.30,12.65.ESI-MS m/z:C21H35BrO5 469.3(M+Na)+:471.3(M+2+Na)+＝1:1。
实施例5：中间产物D7的制备
将DHA(1g，3.5mmol)溶于200mL二氯甲烷中配成溶液，在室温条件下加入7-溴-1-庚醇(0.553mL，3.6mmol)，再加入4滴三氟化硼***，N2保护，室温反应12h，TLC监测反应。反应结束，加入200mL饱和碳酸氢钠、二氯甲烷萃取三次，再加入无水碳酸钠干燥，过滤拌样，柱层析得中间产物D7，产率13.29％。
结构验证：
β-isomer；1H NMR(600MHz,Chloroform-d)δ5.38(s,1H),4.77(dd,J＝3.5,1.0Hz,1H),3.82(dt,J＝9.6,6.6Hz,1H),3.42–3.30(m,3H),2.67–2.51(m,1H),2.40–2.32(m,1H),2.07–1.99(m,1H),1.90–1.71(m,5H),1.63(dq,J＝13.1,3.3Hz,1H),1.58–1.44(m,5H),1.44(s,3H),1.42–1.40(m,1H),1.39–1.29(m,6H),1.24–1.17(m,1H),0.95(d,J＝6.3Hz,3H),0.90(d,J＝7.4Hz,3H).13C NMR(150MHz,Chloroform-d)δ104.06,101.97,87.91,81.16,68.32,52.61,44.50,37.51,36.46,34.68,33.95,32.74,30.95,29.55,28.47,28.13,26.24,26.08,24.70,24.49,20.40,13.05.ESI-MS m/z:C22H37BrO5 483.1724(M+Na)+:485.1708(M+2+Na)+＝1:1。
α-isomer；1H NMR(600MHz,Chloroform-d)δ5.33(s,1H),4.41(d,J＝9.2Hz,1H),4.04–3.88(m,1H),3.45–3.29(m,3H),2.46–2.33(m,2H),2.02(ddd,J＝14.6,5.0,3.0Hz,1H),1.86(tt,J＝14.5,7.0Hz,3H),1.76(dq,J＝13.6,3.8Hz,1H),1.68(dq,J＝13.3,3.4Hz,1H),1.60–1.45(m,4H),1.44(s,3H),1.42–1.27(m,9H),1.04–0.97(m,1H),0.95(d,J＝6.3Hz,3H),0.88(d,J＝7.1Hz,3H).13C NMR(150MHz,Chloroform-d)δ104.25,100.12,91.21,80.36,69.02,51.69,45.35,37.39,36.35,34.27,34.01,32.76,32.64,29.45,28.54,28.12,26.08,25.83,24.73,22.23,20.30,12.65.ESI-MS m/z:C22H37BrO5 483.1724(M+Na)+:485.1708(M+2+Na)+＝1:1。
实施例6：中间产物D8的制备
将DHA(1g，3.5mmol)溶于200mL二氯甲烷中配成溶液，在室温条件下加入8-溴-1-辛醇(0.617mL，3.6mmol)，再加入4滴三氟化硼***，N2保护，室温反应12h，TLC监测反应。反应结束，加入200mL饱和碳酸氢钠、二氯甲烷萃取三次，再加入无水碳酸钠干燥，过滤拌样，柱层析得中间产物D8，产率19.07％。
结构验证：
β-isomer；1H NMR(600MHz,Chloroform-d)δ5.38(s,1H),4.76(d,J＝3.5Hz,1H),3.83(ddt,J＝22.6,9.7,6.6Hz,1H),3.39(td,J＝6.9,1.7Hz,2H),3.35(dt,J＝9.7,6.5Hz,1H),2.60(qt,J＝7.4,4.0Hz,1H),2.36(td,J＝14.0,4.0Hz,1H),2.02(ddd,J＝14.7,5.2,3.2Hz,1H),1.84(ddd,J＝14.4,8.2,5.5Hz,3H),1.81–1.67(m,2H),1.64(t,J＝3.6Hz,1H),1.61–1.51(m,3H),1.51–1.44(m,2H),1.43(s,3H),1.32(dq,J＝8.7,5.6,4.5Hz,9H),1.18(d,J＝7.2Hz,1H),0.95(d,J＝6.3Hz,3H),0.89(d,J＝7.3Hz,3H).13C NMR(150MHz,Chloroform-d)δ104.04,101.95,87.91,81.16,68.39,52.61,44.50,37.50,36.46,34.70,33.98,32.80,30.95,29.62,29.13,28.72,28.09,26.24,26.15,24.70,24.48,20.40,13.05.ESI-MS m/z:C23H39BrO5 497.3(M+Na)+:499.3(M+2+Na)+＝1:1。
α-isomer；1H NMR(600MHz,Chloroform-d)δ5.32(s,1H),4.41(d,J＝9.2Hz,1H),4.02–3.89(m,1H),3.40(t,J＝6.9Hz,3H),2.48–2.31(m,2H),2.01(ddd,J＝14.6,5.0,3.0Hz,1H),1.91–1.81(m,3H),1.75(dq,J＝13.6,3.9Hz,1H),1.71–1.64(m,2H),1.63–1.45(m,5H),1.43(s,3H),1.42–1.36(m,2H),1.31(dd,J＝5.8,3.3Hz,5H),1.27(d,J＝6.9Hz,1H),1.00(td,J＝12.7,12.3,3.6Hz,1H),0.95(d,J＝6.2Hz,3H),0.93–0.89(m,1H),0.87(d,J＝7.1Hz,3H).13CNMR(150MHz,Chloroform-d)δ104.23,100.10,91.20,80.35,69.09,51.69,45.35,37.38,36.35,34.27,34.04,33.99,32.81,32.76,29.50,29.19,28.70,28.12,25.90,24.72,22.22,20.30,12.64.ESI-MS m/z:C23H39BrO5 497.3(M+Na)+:499.3(M+2+Na)+＝1:1。
实施例7：中间产物D9的制备
将DHA(1g，3.5mmol)溶于200mL二氯甲烷中配成溶液，在室温条件下加入9-溴-1-壬醇(0.663mL，3.6mmol)，再加入4滴三氟化硼***，N2保护，室温反应12h，TLC监测反应。反应结束，加入200mL饱和碳酸氢钠、二氯甲烷萃取三次，再加入无水碳酸钠干燥，过滤拌样，柱层析得中间产物D9，产率15.14％。
结构验证：
β-isomer；1H NMR(600MHz,Chloroform-d)δ5.39(s,1H),4.77(d,J＝3.5Hz,1H),3.82(dt,J＝9.6,6.6Hz,1H),3.49–3.33(m,3H),2.61(qdd,J＝7.4,4.6,3.5Hz,1H),2.41–2.25(m,1H),2.03(ddd,J＝14.6,5.0,3.0Hz,1H),1.92–1.77(m,4H),1.74(dq,J＝14.3,4.0Hz,1H),1.63(dq,J＝13.1,3.4Hz,1H),1.57–1.45(m,4H),1.44(s,3H),1.42(d,J＝9.8Hz,2H),1.38–1.27(m,10H),1.24–1.17(m,1H),0.95(d,J＝6.3Hz,3H),0.89(d,J＝7.4Hz,3H).13C NMR(150MHz,Chloroform-d)δ104.05,101.95,87.91,81.17,68.41,52.62,44.51,37.50,36.47,34.70,34.02,32.84,30.96,29.64,29.40,29.22,28.71,28.18,26.25,26.20,24.71,24.47,20.40,13.05.ESI-MS m/z:C24H41BrO5 511.4(M+Na)+:513.3(M+2+Na)+＝1:1。
α-isomer；1H NMR(600MHz,Chloroform-d)δ5.33(s,1H),4.41(d,J＝9.2Hz,1H),3.95(ddd,J＝9.6,7.0,5.8Hz,1H),3.47–3.31(m,3H),2.49–2.30(m,2H),2.06–1.99(m,1H),1.95–1.87(m,1H),1.87–1.81(m,4H),1.77(tq,J＝13.6,3.8Hz,1H),1.68(dq,J＝13.4,3.4Hz,1H),1.58–1.46(m,4H),1.44(s,3H),1.41(q,J＝6.2,5.4Hz,3H),1.31–1.29(m,6H),1.22–1.14(m,1H),1.08–0.98(m,2H),0.95(d,J＝6.3Hz,3H),0.88(d,J＝7.2Hz,3H).13C NMR(150MHz,Chloroform-d)δ104.24,100.10,91.20,80.35,69.14,51.69,45.35,37.39,36.35,34.27,34.06,32.84,32.65,29.53,29.37,29.29,28.71,28.16,26.08,25.95,24.73,22.23,20.30,12.64.ESI-MS m/z:C24H41BrO5 511.4(M+Na)+:513.3(M+2+Na)+＝1:1。
实施例8：中间产物D10的制备
将DHA(1g，3.5mmol)溶于200mL二氯甲烷中配成溶液，在室温条件下加入10-溴-1-葵醇(0.719mL，3.6mmol)，再加入4滴三氟化硼***，N2保护，室温反应12h，TLC监测反应。反应结束，加入200mL饱和碳酸氢钠、二氯甲烷萃取三次，再加入无水碳酸钠干燥，过滤拌样，柱层析得中间产物D10，产率6.77％。
结构验证：
β-isomer；1H NMR(600MHz,Chloroform-d)δ5.41(s,1H),4.80(d,J＝3.6Hz,1H),3.86(ddt,J＝21.0,9.6,6.6Hz,1H),3.52–3.36(m,3H),2.63(qdd,J＝7.4,4.6,3.5Hz,1H),2.36(dddd,J＝37.8,14.6,13.5,3.9Hz,1H),2.05(dtd,J＝14.1,5.4,3.1Hz,1H),1.95–1.80(m,4H),1.80–1.69(m,1H),1.65(dp,J＝12.8,2.9Hz,1H),1.60–1.47(m,4H),1.46(d,J＝9.2Hz,3H),1.43(d,J＝8.9Hz,1H),1.32(d,J＝9.8Hz,12H),1.27–1.18(m,2H),0.98(d,J＝6.2Hz,3H),0.92(d,J＝7.2Hz,3H).13C NMR(150MHz,Chloroform-d)δ104.04,101.94,87.91,81.17,68.42,52.62,44.51,37.50,36.47,34.71,34.04,32.84,30.96,29.65,29.49,29.37,29.28,28.77,28.19,26.25,26.22,24.71,24.47,20.40,13.05.ESI-MS m/z:C25H43BrO5 525.4(M+Na)+:527.4(M+2+Na)+＝1:1。
α-isomer；1H NMR(600MHz,Chloroform-d)δ5.33(s,1H),4.41(d,J＝9.2Hz,1H),3.95(ddd,J＝9.5,7.1,5.8Hz,1H),3.47–3.27(m,3H),2.46–2.29(m,2H),2.02(ddd,J＝14.5,4.9,3.0Hz,1H),1.91–1.81(m,3H),1.76(dq,J＝13.5,3.7Hz,1H),1.68(dq,J＝13.4,3.4Hz,1H),1.59–1.46(m,4H),1.44(s,3H),1.43–1.39(m,2H),1.37–1.26(m,13H),1.10(s,1H),1.05–0.98(m,1H),0.95(d,J＝6.3Hz,3H),0.88(d,J＝7.8Hz,3H).13C NMR(150MHz,Chloroform-d)δ104.24,100.10,91.20,80.36,69.18,51.69,45.36,37.39,36.36,34.28,34.08,32.85,32.65,29.71,29.55,29.46,29.37,28.75,28.18,26.08,25.98,24.73,22.23,20.30,12.64.ESI-MS m/z:C25H43BrO5 525.4(M+Na)+:527.4(M+2+Na)+＝1:1。
实施例9：中间产物D11的制备
将DHA(1g，3.5mmol)溶于200mL二氯甲烷中配成溶液，在室温条件下加入11-溴-1-十一醇(0.9g，3.6mmol)，再加入4滴三氟化硼***，N2保护，室温反应12h，TLC监测反应。反应结束，加入200mL饱和碳酸氢钠、二氯甲烷萃取三次，再加入无水碳酸钠干燥，过滤拌样，柱层析得中间产物D11，产率12.14％。
结构验证：
β-isomer；1H NMR(600MHz,Chloroform-d)δ5.38(s,1H),4.77(d,J＝3.5Hz,1H),3.81(dt,J＝9.6,6.6Hz,1H),3.42–3.32(m,3H),2.68–2.56(m,1H),2.36(ddd,J＝14.6,13.5,4.0Hz,1H),2.03(ddd,J＝14.6,5.0,3.0Hz,1H),1.92–1.80(m,4H),1.73(dq,J＝14.4,3.9Hz,1H),1.64–1.59(m,1H),1.58–1.45(m,4H),1.43(s,3H),1.42–1.39(m,2H),1.35–1.23(m,15H),0.95(d,J＝6.3Hz,3H),0.89(d,J＝7.4Hz,3H).13C NMR(150MHz,Chloroform-d)δ104.05,101.94,87.91,81.18,68.44,52.61,44.51,37.49,36.47,34.70,34.06,32.84,30.96,29.71,29.65,29.56,29.47,29.44,29.31,28.79,28.19,26.24,24.70,24.47,20.40,13.05.ESI-MS m/z:C26H45BrO5539.2347(M+Na)+:541.2331(M+2+Na)+＝1:1。
实施例10：中间产物D12的制备
将DHA(1g，3.5mmol)溶于200mL二氯甲烷中配成溶液，在室温条件下加入12-溴-1-十二醇(0.855mL，3.6mmol)，再加入4滴三氟化硼***，N2保护，室温反应12h，TLC监测反应。反应结束，加入200mL饱和碳酸氢钠、二氯甲烷萃取三次，再加入无水碳酸钠干燥，过滤拌样，柱层析得中间产物D12，产率13.12％。
结构验证：
β-isomer；1H NMR(600MHz,Chloroform-d)δ5.39(s,1H),4.77(d,J＝2.5Hz,1H),3.82(dt,J＝9.6,6.6Hz,1H),3.40(t,J＝6.9Hz,2H),3.36(dt,J＝9.7,6.4Hz,1H),2.65–2.55(m,1H),2.37(ddd,J＝14.6,13.5,4.0Hz,1H),2.03(ddd,J＝14.6,5.0,3.0Hz,1H),1.92–1.78(m,4H),1.74(dq,J＝14.2,3.8Hz,1H),1.62(dq,J＝13.2,3.4Hz,1H),1.56–1.44(m,4H),1.44(s,3H),1.43–1.39(m,2H),1.36–1.24(m,17H),0.95(d,J＝6.4Hz,3H),0.90(d,J＝7.4Hz,3H).13CNMR(150MHz,Chloroform-d)δ104.04,101.94,87.92,81.18,68.45,52.62,44.52,37.49,36.47,34.71,34.07,32.85,30.97,29.66,29.60,29.55(×2),29.46,29.33,28.79,28.19,26.25(×2),24.71,24.47,20.40,13.05.ESI-MS m/z:C27H47BrO5553.4(M+Na)+:555.4(M+2+Na)+＝1:1。
α-isomer；1H NMR(600MHz,Chloroform-d)δ5.33(s,1H),4.41(d,J＝9.2Hz,1H),3.98–3.85(m,1H),3.44–3.30(m,3H),2.45–2.31(m,2H),2.02(ddd,J＝14.5,4.9,2.9Hz,1H),1.90–1.82(m,3H),1.76(dq,J＝13.6,3.7Hz,1H),1.68(dq,J＝13.4,3.5Hz,1H),1.60–1.46(m,5H),1.44(s,3H),1.43–1.39(m,2H),1.38–1.27(m,13H),1.24–1.09(m,2H),1.03–0.97(m,1H),0.95(d,J＝6.3Hz,3H),0.91(ddd,J＝9.3,5.3,2.6Hz,1H),0.88(d,J＝7.2Hz,3H).13C NMR(150MHz,Chloroform-d)δ104.24,100.10,91.20,80.36,69.22,51.69,45.36,37.39,36.36,34.28,34.09,32.86,32.65,29.57(×2),29.54,29.52,29.44,29.42,28.78,28.19,26.08,26.00,24.73,22.23,20.30,12.64.ESI-MS m/z:C27H47BrO5 553.4(M+Na)+:555.4(M+2+Na)+＝1:1。
实施例11：化合物D3-T的制备
将中间体D3(1eq)，三苯基磷(2eq)，碳酸钾70mg溶于5-10mL乙腈中，N2保护，60℃回流24h。TLC监测，待反应结束后过滤，旋干样品，柱层析得化合物D3-T，产率26.19％。
结构验证：
β-isomer；1H NMR(600MHz,Chloroform-d)δ7.85–7.77(m,9H),7.69(td,J＝7.8,3.4Hz,6H),5.26(s,1H),4.72(d,J＝3.5Hz,1H),4.04–3.87(m,2H),3.82–3.67(m,2H),2.57(qt,J＝7.4,4.1Hz,1H),2.32(td,J＝14.0,3.9Hz,1H),1.99(ddd,J＝14.6,4.9,3.0Hz,2H),1.96–1.90(m,2H),1.84(ddt,J＝13.5,6.7,3.5Hz,1H),1.73–1.48(m,4H),1.44–1.38(m,2H),1.36(s,3H),1.19(td,J＝11.0,6.2Hz,1H),0.92(d,J＝6.0Hz,3H),0.83(d,J＝7.3Hz,3H).13C NMR(150MHz,Chloroform-d)δ135.13(d,J＝3.0Hz,Ph-C),133.67(d,J＝9.0Hz,Ph-C),130.55(d,J＝12.0Hz,Ph-C),118.18(d,J＝85.5Hz,Ph-C),104.11,101.78,87.78,80.88,67.06,66.92,52.42,44.20,37.35,36.33,34.56,30.79,29.68,26.09,24.61(d,J＝7.5Hz,Ph-C),23.11(d,J＝3.0Hz,Ph-C),20.34,13.19.ESI-MS m/z C36H44O5P+587.4(M-Br)+。
实施例12：化合物D4-T的制备
将中间体D4(1eq)，三苯基磷(2eq)，碳酸钾70mg溶于5-10mL乙腈中，N2保护，60℃回流24h。TLC监测，待反应结束后过滤，旋干样品，柱层析得化合物D4-T，产率21.09％。
结构验证：
α：β＝5:4；1H NMR(600MHz,Chloroform-d)δ7.88–7.75(m,9H),7.72–7.66(m,6H),5.31/5.24(s,1H),4.66/4.44(d,J＝3.5Hz and J＝9.2Hz,1H),4.06–3.95/3.94–3.88(m,1H),3.82–3.74(m,3H),3.61–3.53/3.37–3.33(m,1H),2.79–2.59(m,1H),2.53(tdd,J＝10.0,6.7,3.3Hz,1H),2.43–2.16(m,5H),2.04–1.93(m,3H),1.79–1.65(m,2H),1.58–1.44(m,3H),1.40/1.39(s,3H),0.93/0.91(d,J＝6.0Hz,3H),0.75/0.69(d,J＝3Hz,3H).13C NMR(150MHz,Chloroform-d)δ134.97/134.92(d,J＝3.0Hz,Ph-C),133.81/133.72/133.69(d,J＝9.0Hz,Ph-C),130.48/130.46(d,J＝12.0Hz,Ph-C),118.39/118.33(d,J＝85.5Hz,Ph-C),104.07/103.99,101.88/99.84,91.20/87.80,80.96/80.59,67.53/66.66,59.90/59.52,52.46/51.76,45.41/45.31,38.15,37.36/37.28,36.38/36.27,34.51/34.19,32.96,31.24/30.77,26.16/25.70,24.65/24.42,22.69,20.37/20.28,13.01/12.63.ESI-MS m/z C37H46O5P+601.4(M-Br)+。
实施例13：化合物D5-T的制备
将中间体D5(1eq)，三苯基磷(2eq)，碳酸钾70mg溶于5-10mL乙腈中，N2保护，60℃回流24h。TLC监测，待反应结束后过滤，旋干样品，柱层析得化合物D5-T，产率43.12％。
结构验证：
α：β＝1:5；1H NMR(600MHz,Chloroform-d)δ7.85–7.82/7.68 7.63(m,6H),7.78–7.76/7.56–7.52(m,3H),7.71–7.70/7.48–7.43(m,6H),5.32/5.37(s,1H),4.67/4.88(d,J＝3.6Hz and 5.4Hz,1H),3.84–3.77(m,2H),3.72(dt,J＝9.7,6.4Hz,2H),3.28(dt,J＝9.7,6.5Hz,1H),2.61–2.50(m,1H),2.34(td,J＝14.0,4.0Hz,2H),2.00(ddd,J＝14.5,4.9,3.1Hz,2H),1.85(ddd,J＝10.1,6.4,3.2Hz,2H),1.54–1.41(m,4H),1.39/1.40(s,3H),1.34–1.27(m,3H),1.22–1.12(m,3H),0.93(d,J＝6.3Hz,3H),0.80(d,J＝7.3Hz,3H).13CNMR(150MHz,Chloroform-d)δ135.00(d,J＝3.0Hz,Ph-C),133.77(d,J＝9.0Hz,Ph-C),133.70(d,J＝7.5Hz,Ph-C),132.09(d,J＝9.0Hz,Ph-C),131.97,131.96,130.51/128.51(d,J＝12.0Hz,Ph-C),118.43(d,J＝85.5Hz,Ph-C),104.04,101.98/102.15,87.90/88.30,81.12/80.53,67.89,59.52,55.62/52.55,44.41,38.15,37.40,36.43,34.60,31.93/31.24,30.87,29.16,26.19,24.67,24.46,20.37,14.12/13.09.ESI-MS m/zC38H48O5P+615.5(M-Br)+。
实施例14：化合物D6-T的制备
将中间体D6(1eq)，三苯基磷(2eq)，碳酸钾70mg溶于5-10mL乙腈中，N2保护，60℃回流24h。TLC监测，待反应结束后过滤，旋干样品，柱层析得化合物D6-T，产率25.52％
结构验证：
α：β＝1:1；1H NMR(600MHz,Chloroform-d)δ7.85(dddd,J＝14.0,12.5,8.4,1.3Hz,6H),7.78(tt,J＝7.4,1.6Hz,3H),7.70(ddt,J＝11.0,7.4,3.3Hz,6H),5.33/5.31(s,1H),4.70/4.38(d,J＝3.5Hz and 9.2Hz,1H),3.93–3.69(m,3H),3.38–3.24(m,1H),2.38–2.29(m,1H),2.04–1.95(m,1H),1.85(ddt,J＝13.9,7.0,3.6Hz,1H),1.78–1.73(m,2H),1.71–1.66(m,3H),1.64–1.58(m,3H),1.56–1.42(m,5H),1.40/1.39(s,3H),1.37–1.25(m,4H),0.94/0.93(d,J＝6.6Hz,3H),0.84/0.82(d,J＝7.2Hz,3H).13C NMR(150MHz,Chloroform-d)δ134.98/134.95(d,J＝3.0Hz,Ph-C),133.75/133.69(d,J＝9.0Hz,Ph-C),130.50/130.46(d,J＝12.0Hz,Ph-C),118.50/118.43(d,J＝85.5Hz,Ph-C),104.18/104.03,101.91/100.07,91.19/87.89,81.16/80.45,68.94/68.29,52.58/51.70,45.36/44.45,38.15,37.41/37.33,36.45/36.35,34.59/34.23,32.74,31.24/30.92,29.25/28.90,26.22/26.08,25.97/25.48,24.68/24.46,22.21,20.37/20.29,14.13/13.87,13.06/12.67.ESI-MS m/z C39H50O5P+629.5(M-Br)+。
实施例15：化合物D7-T的制备
将中间体D7(1eq)，三苯基磷(2eq)，碳酸钾70mg溶于5-10mL乙腈中，N2保护，60℃回流24h。TLC监测，待反应结束后过滤，旋干样品，柱层析得化合物D7-T，产率25.52％。
结构验证：
α：β＝1:3；1H NMR(600MHz,Chloroform-d)δ7.87–7.75(m,9H),7.70(td,J＝7.7,3.3Hz,6H),5.34/5.31(s,1H),4.71/4.38(d,J＝3.6Hz and 9.2Hz,1H),3.90–3.65(m,3H),3.36–3.24(m,1H),2.38–2.27(m,2H),2.24–1.93(m,2H),1.84–1.82(m,2H),1.77–1.65(m,2H),1.54–1.43(m,4H),1.40/1.39(s,3H),1.33–1.13(m,10H),0.94/0.93(d,J＝6.0Hz,3H),0.84/0.81(d,J＝7.2Hz,3H).13C NMR(150MHz,Chloroform-d)δ135.02/134.98(d,J＝3.0Hz,Ph-C),133.71/133.68(d,J＝9.0Hz,Ph-C),130.51/130.48(d,J＝12.0Hz,Ph-C),118.40/118.44(d,J＝85.5Hz,Ph-C),104.21/104.04,101.94/100.13,91.18/87.90,81.19/80.44,69.14/68.38,52.59/51.69,45.35/44.48,37.42/37.34,36.45/36.34,34.62/34.23,32.71,30.92,30.26,30.16,29.54/29.35,29.04/28.80,26.23/26.07,25.82/25.50,24.68/24.44,22.46/22.21,20.39/20.29,13.06/12.66.ESI-MS m/zC40H52O5P+643.5(M-Br)+。
实施例16：化合物D8-T的制备
将中间体D8(1eq)，三苯基磷(2eq)，碳酸钾70mg溶于5-10mL乙腈中，N2保护，60℃回流24h。TLC监测，待反应结束后过滤，旋干样品，柱层析得化合物D8-T，产率22.36％。
结构验证：
α：β＝1:1；β-isomer；1H NMR(600MHz,Chloroform-d)δ7.87–7.76(m,10H),7.72–7.67(m,5H),5.35/5.31(s,1H),4.72/4.38(d,J＝3.5and 9.3Hz,1H),3.92–3.69(m,3H),3.63/3.58(t,J＝6.6Hz,1H),3.38–3.26(m,2H),2.64–2.29(m,2H),2.03–1.96(m,2H),1.94–1.80(m,4H),1.80–1.65(m,3H),1.56–1.44(m,5H),1.41/1.40(s,1H),1.34–1.27(m,3H),1.21–1.13(m,3H),1.07–0.95(m,1H),0.94/0.93(d,J＝6.6Hz,3H),0.91–0.87(m,1H),0.86/0.84(d,J＝7.2Hz,3H).13C NMR(150MHz,Chloroform-d)δ135.02/134.99(d,J＝3.0Hz,Ph-C),133.70/133.68(d,J＝9.0Hz,Ph-C),132.08(d,J＝9.0Hz,Ph-C),131.97(d,J＝3.0Hz,Ph-C),130.51/130.48(d,J＝12.0Hz,Ph-C),128.51(d,J＝12.0Hz,Ph-C),118.44/118.40(d,J＝85.5Hz,Ph-C),104.21/104.03,101.90/100.13,91.19/87.90,81.18/80.43,69.21/68.41,52.60/51.69,45.35/44.48,38.14,37.44/37.35,36.45/36.35,34.87/34.84,34.23,31.92,31.24/30.94,29.56/29.39,29.21/29.01,28.95/28.84,26.23/26.13,26.08/25.79,24.68/24.45,22.59/22.22,20.39/20.29,13.06/12.66.ESI-MS m/z C41H54O5P+657.5(M-Br)+。
实施例17：化合物D9-T的制备
将中间体D9(1eq)，三苯基磷(2eq)，碳酸钾70mg溶于5-10mL乙腈中，N2保护，60℃回流24h。TLC监测，待反应结束后过滤，旋干样品，柱层析得化合物D9-T，产率17.71％。
结构验证:
α：β＝1:4；β-isomer；1H NMR(600MHz,Chloroform-d)δ7.87(dddd,J＝12.5,6.7,3.2,1.3Hz,6H),7.83–7.79(m,3H),7.76–7.69(m,6H),5.39/5.35(s,1H),4.77/4.42(d,J＝3.0Hz and9.2Hz,1H),3.99–3.61(m,4H),3.42–3.31(m,1H),2.44–2.30(m,1H),2.07–1.98(m,1H),1.95–1.68(m,7H),1.59–1.47(m,4H),1.46–1.38(m,4H),1.37–1.28(m,6H),1.24–1.16(m,5H),0.97/0.96(d,J＝6.6Hz,3H),0.89/0.88(d,J＝7.2Hz,3H).13C NMR(150MHz,Chloroform-d)δ134.97(d,J＝3.0Hz,Ph-C),133.73/133.71(d,J＝10.5Hz,Ph-C),132.09(d,J＝9.0Hz,Ph-C),131.95(d,J＝3.0Hz,Ph-C),130.48/130.43(d,J＝13.5Hz,Ph-C),128.54/128.51(d,J＝12.0Hz,Ph-C),118.48(d,J＝85.5Hz,Ph-C),104.21/104.03,101.93/100.10,91.20/87.91,81.20/80.41,69.23/68.45,52.61/51.70,45.37/44.51,38.15,37.44/37.36,36.47/36.36,34.24,32.71,31.24/30.96,29.66,29.45/29.36,29.17,26.08,25.84,24.70,22.56,22.27/22.23,20.40/20.29,14.13/13.84,13.06/12.66.ESI-MS m/z C42H56O5P+671.5(M-Br)+。
实施例18：化合物D10-T的制备
将中间体D10(1eq)，三苯基磷(2eq)，碳酸钾70mg溶于5-10mL乙腈中，N2保护，60℃回流24h。TLC监测，待反应结束后过滤，旋干样品，柱层析得化合物D10-T，产率20.86％。
结构验证：
α：β＝1:10；1H NMR(600MHz,Chloroform-d)δ7.87–7.75(m,9H),7.70(td,J＝7.8,3.4Hz,6H),5.36/5.31(s,1H),4.74/4.39(d,J＝3.0Hz and 9.2Hz,1H),3.94–3.56(m,4H),3.41–3.28(m,1H),2.41–2.28(m,2H),1.92–1.81(m,4H),1.79–1.66(m,3H),1.56–1.43(m,5H),1.41(s,3H),1.34–1.25(m,4H),1.22–1.12(m,8H),1.02–0.95(m,1H),0.94/0.93(d,J＝6.6Hz,3H),0.86/0.85(d,J＝7.2Hz,3H).13C NMR(150MHz,Chloroform-d)δ135.03/130.54(d,J＝3.0Hz,Ph-C),134.67/132.08(d,J＝9.0Hz,Ph-C),130.52/130.49(d,J＝10.5Hz,Ph-C),128.52(d,J＝12.0Hz,Ph-C),118.43/118.40(d,J＝85.5Hz,Ph-C),104.22/104.03,100.14,91.19,80.42,69.29,52.60/51.69,45.35,37.36,36.35,34.24,32.70/32.62,29.51,29.36,29.26,29.11,29.02,26.07,25.90,24.70,24.45,22.61,22.22,20.40,20.29,13.05/12.65.ESI-MS m/z C43H58O5P+685.5(M-Br)+。
实施例18：化合物D11-T的制备
将中间体D11(1eq)，三苯基磷(2eq)，碳酸钾70mg溶于5-10mL乙腈中，N2保护，60℃回流24h。TLC监测，待反应结束后过滤，旋干样品，柱层析得化合物D11-T，产率18.18％。
结构验证：
α：β＝1:4；1H NMR(600MHz,Chloroform-d)δ7.87–7.80/7.67–7.62(m,6H),7.90–7.79/7.56–7.52(m,3H),7.70/7.45(ddd,J＝11.2,6.4,3.4Hz,6H),5.37/5.32(s,1H),4.75/4.40(d,J＝3.0Hz and 9.2Hz,1H),3.96–3.68(m,3H),3.64–3.30(m,1H),2.43–2.32(m,2H),2.05–1.97(m,1H),1.94–1.78(m,5H),1.77–1.65(m,3H),1.58–1.44(m,4H),1.42/1.41(s,3H),1.40–1.37(m,1H),1.36–1.27(m,5H),1.22–1.14(m,8H),1.03–0.97(m,1H),0.95/0.92(d,J＝6.6Hz,3H),0.86(d,J＝7.2Hz,3H).13C NMR(150MHz,Chloroform-d)δ135.00(d,J＝3.0Hz,Ph-C),133.71/133.69(d,J＝9.0Hz,Ph-C),132.09(d,J＝10.5Hz,Ph-C),131.97(d,J＝3.0Hz,Ph-C),130.49/130.47(d,J＝12.0Hz,Ph-C),128.51(d,J＝12.0Hz,Ph-C),118.47/118.44(d,J＝85.5Hz,Ph-C),104.22/104.03,101.92/100.13,91.20/87.91,81.19/80.41,69.30/68.46,52.61/51.69,45.36/44.51,37.46/37.37,36.46/36.35,34.68/34.25,31.24,29.52/29.49,29.41,29.37,29.31,29.21,29.15,29.09,26.07,25.93,24.71/24.46,22.92,22.64/22.60,22.22,20.40/20.29,13.06/12.65.ESI-MS m/z C44H60O5P+699.5(M-Br)+。
实施例19：化合物D12-T的制备
将中间体D12(1eq)，三苯基磷(2eq)，碳酸钾70mg溶于5-10mL乙腈中，N2保护，60℃回流24h。TLC监测，待反应结束后过滤，旋干样品，柱层析得化合物D12-T，产率28.93％
结构验证：
α：β＝1:10；1H NMR(600MHz,Chloroform-d)δ7.83/7.65(ddt,J＝12.5,7.0,1.3Hz,6H),7.80–7.76/7.55–7.52(m,3H),7.73–7.67/7.47–7.44(m,6H),5.32/5.37(s,1H),4.40/4.75(d,J＝9.2Hz and 3.6Hz,1H),3.93(ddd,J＝9.6,7.1,5.8Hz,1H),3.83–3.65(m,2H),3.41–3.32(m,1H),2.37(dddd,J＝17.4,14.5,10.2,4.3Hz,2H),2.05–1.93(m,1H),1.86(ddt,J＝13.7,6.8,3.5Hz,1H),1.74(dt,J＝13.6,3.8Hz,2H),1.68(dq,J＝13.3,3.4Hz,1H),1.56–1.43(m,4H),1.42–1.39(m,4H),1.35–1.25(m,7H),1.23–1.15(m,11H),1.10(s,2H),1.03–0.96(m,1H),0.94(d,J＝6.2Hz,3H),0.89–0.82(m,3H).13C NMR(150MHz,Chloroform-d)δ134.98/131.96(d,J＝3.0Hz,Ph-C),133.70/132.09(d,J＝9.0Hz,Ph-C),130.48/130.47(d,J＝12.0Hz,Ph-C),128.51(d,J＝12.0Hz,Ph-C),118.42/118.41(d,J＝85.5Hz,Ph-C),104.22/104.03,101.93/100.13,91.20,80.40,69.30,51.69,45.36,38.15,37.37,36.35,34.25,32.69,31.24,30.38(d,J＝15.0Hz),29.55,29.48,29.45,29.37,29.18,29.11,26.07,25.97,24.71,22.92,22.62(d,J＝4.5Hz),22.22,20.30,12.65.ESI-MS m/z C45H62O5P+713.6(M-Br)+。
实验例1：药物IC50值测定
一、实验材料
人膀胱癌细胞系J82购自上海兴泊生物科技有限公司；
人膀胱癌细胞系T24购自上海兴泊生物科技有限公司；
人肺癌细胞系A549购自上海兴泊生物科技有限公司；
人卵巢癌细胞系OVCAR3购自武汉细胞所；
人卵巢癌细胞系SKOV3来自湘雅医院。
MTT购自Solarbio公司。
二、实验方法及结果
取处于对数期的人膀胱癌细胞(J82、T24)、人卵巢癌细胞(OVCAR3、SKOV3)和人肺癌细胞A549分别按照每孔5000个细胞进行种板，将接种完的96孔培养板放置于培养箱中过夜，用不同浓度的化合物D3-T、化合物D4-T、化合物D5-T、化合物D6-T、化合物D7-T、化合物D8-T、化合物D9-T、化合物D10-T、化合物D11-T、化合物D12-T处理96孔板，处理完成后将96孔培养板均放回培养箱中培养72小时，然后用MTT比色法检测细胞生存率，并分别计算IC50值，实验结果如表1所示。
表1 D3-T～D12-T对5株肿瘤细胞的半数抑制浓度(IC50)
实验例2：细胞克隆试验
一、实验材料
10％的***购自国药集团化学试剂有限公司；
结晶紫染液购自Sigma-Aldrich公司。
二、实验方法及结果
取处于对数生长期的人膀胱癌细胞系J82、T24，分别按照每孔1000个细胞接种于24孔培养板，将接种完的培养板均放置在培养箱中过夜，使细胞贴壁；人膀胱癌细胞系J82、T24分别给予0nM、6.25nM、12.5nM、25nM、50nM的药物(药物为D8-T和DHA)处理；处理完后将培养板均放回培养箱中继续培养一周；待细胞融合至80％后，倒掉培养液，用PBS洗一遍，10％的***固定1个小时，用并500μL结晶紫染液染色一个小时，最后回收结晶紫染液；之后，分别将24孔板流水冲洗干净，并将24孔板倒置放在滤纸上，干燥后用相机拍摄图像并用酶标仪(Biotek，SYNERGY HTX，Vermont，USA)进行定量分析，实验结果如图2-3所示。
实验例3：细胞划痕试验
取处于对数生长期的人膀胱癌细胞系J82分别按照每孔3×105个细胞接种于12孔培养板，将接种完的培养板均放置在培养箱中使细胞融合至70％-80％。用marker笔在12孔板背后用直尺在中间划一个十字作为固定监测点，使前后观察时位置固定。用10μL枪头比着直尺背后的横线划痕。PBS洗细胞一次，去除划下的细胞，加入无血清培养基。然后膀胱癌细胞系J82分别给予12.5nM、25nM、50nM的药物(药物为D8-T和DHA)处理，放入37度5％CO2培养箱培养。分别于0，24，48小时用显微镜(Leica，DFC450C，Wetzlar，Germany)拍摄图像。实验结果如图4-5所示。由图可以看出，化合物对人膀胱癌细胞系T24、人膀胱癌细胞系UMUC3、人肺癌细胞系A549的迁移抑制效果明显优于双氢青蒿素。
Claims (10)
1.一种双氢青蒿素衍生物，其特征是，所述双氢青蒿素衍生物的结构为如下式Ⅰ所示：
其中，所述n为3-12，R1为三苯基膦，R2为卤素。
2.根据权利要求1所述的双氢青蒿素衍生物，其特征是，R2为溴。
3.根据权利要求1所述的双氢青蒿素衍生物，其特征是，所述双氢青蒿素衍生物为以下化合物之一：
4.一种如权利要求1所述的双氢青蒿素衍生物，其特征是，所述双氢青蒿素衍生物为式Ⅰ化合物的各光学异构体、各晶型、药学上可接受的无机盐、有机盐或前药。
5.一种如权利要求1-3任一项所述的双氢青蒿素衍生物的制备方法，其特征是，将双氢青蒿素和
反应，n为3-12，R2为卤素，得到中间体，中间体的结构式如下：
中间体和三苯基膦反应，得到双氢青蒿素衍生物。
6.如权利要求5所述的制备方法，其特征是，所述双氢青蒿素和
反应的溶剂为二氯甲烷，催化剂为三氟化硼***。
7.如权利要求5所述的制备方法，其特征是，中间体和三苯基膦反应的溶剂为乙氰，反应体系中还加入有碳酸盐。
8.一种药物组合物，其特征在于，所述的药物组合物包括如权利要求1-4任一项所述的双氢青蒿素衍生物，还包括药学上可接受的赋形剂或载体。
9.一种如权利要求1-4任一所述的双氢青蒿素衍生物在制备抗肿瘤药物中的用途。
10.根据权利要求9所述的应用，其特征在于，所述肿瘤为肺癌、食道癌、胃癌、肝癌、黑色素瘤、胰腺癌、肾癌、白血病、***癌、膀胱癌、神经母细胞瘤、结肠癌、乳腺癌、子宫癌、卵巢癌或鼻咽癌。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111626019.3A CN114380864B (zh) | 2021-12-28 | 2021-12-28 | 一种双氢青蒿素衍生物、制备方法、药物组合物和其在制备抗肿瘤药物中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111626019.3A CN114380864B (zh) | 2021-12-28 | 2021-12-28 | 一种双氢青蒿素衍生物、制备方法、药物组合物和其在制备抗肿瘤药物中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114380864A true CN114380864A (zh) | 2022-04-22 |
| CN114380864B CN114380864B (zh) | 2023-06-23 |
Family
ID=81198020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111626019.3A Active CN114380864B (zh) | 2021-12-28 | 2021-12-28 | 一种双氢青蒿素衍生物、制备方法、药物组合物和其在制备抗肿瘤药物中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114380864B (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114014872A (zh) * | 2021-11-29 | 2022-02-08 | 桂林医学院 | 青蒿琥酯衍生物及其制备方法和应用 |
| CN115340571A (zh) * | 2022-07-05 | 2022-11-15 | 中国中医科学院中药研究所 | 一种新型青蒿素类衍生物、脂质体的制备方法和应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111072699A (zh) * | 2019-12-30 | 2020-04-28 | 广州中医药大学(广州中医药研究院) | 一种羟基自由基比率式荧光探针及其制备方法和应用 |
| WO2020260919A1 (en) * | 2019-06-27 | 2020-12-30 | Centre National De La Recherche Scientifique | Artemisinin-derivative n-heterocyclic carbene gold(i) hybrid complexes |
| CN114014872A (zh) * | 2021-11-29 | 2022-02-08 | 桂林医学院 | 青蒿琥酯衍生物及其制备方法和应用 |
-
2021
- 2021-12-28 CN CN202111626019.3A patent/CN114380864B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020260919A1 (en) * | 2019-06-27 | 2020-12-30 | Centre National De La Recherche Scientifique | Artemisinin-derivative n-heterocyclic carbene gold(i) hybrid complexes |
| CN111072699A (zh) * | 2019-12-30 | 2020-04-28 | 广州中医药大学(广州中医药研究院) | 一种羟基自由基比率式荧光探针及其制备方法和应用 |
| CN114014872A (zh) * | 2021-11-29 | 2022-02-08 | 桂林医学院 | 青蒿琥酯衍生物及其制备方法和应用 |
Non-Patent Citations (2)
| Title |
|---|
| CANGCANG XU ET AL: "Synthesis and biological activities of novel mitochondria-targeted artemisinin ester derivatives" * |
| CANGCANG XU ET AL: "Synthesisand Antitumor Activities of Novel Mitochondria-Targeted Dihydroartemisinin Ether Derivatives Dihydroartemisinin Ether Derivatives" * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114014872A (zh) * | 2021-11-29 | 2022-02-08 | 桂林医学院 | 青蒿琥酯衍生物及其制备方法和应用 |
| CN115340571A (zh) * | 2022-07-05 | 2022-11-15 | 中国中医科学院中药研究所 | 一种新型青蒿素类衍生物、脂质体的制备方法和应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114380864B (zh) | 2023-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113527335A (zh) | 作为egfr抑制剂的大环类化合物及其应用 | |
| CN114380864A (zh) | 一种双氢青蒿素衍生物、制备方法、药物组合物和其在制备抗肿瘤药物中的应用 | |
| CN103781783A (zh) | 作为抗精神病药物的哌嗪取代的苯并噻吩衍生物 | |
| CN109134586B (zh) | 雷公藤红素衍生物及其应用 | |
| WO2013178021A1 (zh) | 吡咯并[2，1—f][1，2，4]三嗪衍生物及其抗肿瘤用途 | |
| CN106831790B (zh) | 7H-吡咯并[2,3-d]嘧啶衍生物 | |
| CN113698401B (zh) | β-榄香烯大环衍生物及其制备方法和应用 | |
| CN112300153A (zh) | 一种杂环化合物、药物组合物和用途 | |
| CN105461697A (zh) | 喹唑啉酮类parp-1抑制剂及含有它们的组合物和抗肿瘤用途 | |
| WO2015096640A1 (zh) | 含噻唑基雷帕霉素类衍生物及其应用 | |
| CN102190658A (zh) | 一类抗肿瘤海洋天然产物ecteinascidins的结构类似物 | |
| CN107286220B (zh) | 1,2,4-三氮唑偶联的二氢杨梅素衍生物及其制备方法和应用 | |
| CN110981882B (zh) | 一类白屈菜碱一氧化氮供体衍生物及其制备方法和用途 | |
| EP3851108B1 (en) | Borate-based drug and use thereof | |
| US20230029066A1 (en) | Crystal forms of fused ring compound, and composition thereof, preparation method therefor and application thereof | |
| CN113024557B (zh) | 一种Peganumine A生物碱结构简化物及其应用 | |
| CN110283162B (zh) | 一种表皮生长因子受体抑制剂及其应用 | |
| CN110903289B (zh) | 嘌呤-氨甲基-吡啶酮衍生物及其制备方法和用途 | |
| CN110092789B (zh) | 一种吲哚并[2,3-b]咔唑衍生物及其应用 | |
| WO2013023620A1 (zh) | 高三尖杉酯碱的胺化衍生物、及其制备方法和应用 | |
| CN110590778B (zh) | 3，10二对甲氧基苯基6，12二氮杂四高立方烷类化合物及合成方法和药物组合物 | |
| CN115785088A (zh) | 作为sos1抑制剂的化合物及其应用 | |
| CN110922450B (zh) | Psma激活式抗肿瘤前药cpt-x及其制备方法和应用 | |
| CN114555607A (zh) | 一类靶向蛋白质水解通路的功能分子及其制备和应用 | |
| CN112694507B (zh) | 四氢蒽醌糖苷类化合物及其在制备抗肿瘤药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |